Clinical trial NCT06683066: Study on Human Bioequivalence of Triprerelin Acetate for Injection
Official title: Study on Human Bioequivalence of Triprerelin Acetate for Injection
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Prostate Cancer (CRPC)
Lead sponsor: The Affiliated Hospital of Qingdao University
Sponsor class: OTHER
Collaborators: name: Shandong Cancer Hospital and Institute
name: Hunan Cancer Hospital
name: Shanxi Province Cancer Hospital
name: The First Affiliated Hospital of Shanxi Medical University
name: The Second Affiliated Hospital of Chongqing Medical University
name: First Affiliated Hospital of Chengdu Medical College
name: Zibo Central Hospital
name: Yuncheng Central Hospital
name: Yichang Central People's Hospital
First posted: 2024-11-12
Enrollment: 120
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To investigate the pharmacokinetics of triprerelin acetate for injection and triprerelin acetate (Dufferin ®) for injection of reference preparation in patients with prostate cancer by single intramusculodynamic injection in fasting state, and to evaluate the bioequivalence of the two formulations in fasting state.


Eligibility criteria: Inclusion Criteria:

1. Voluntarily participate in the test, and sign the informed consent, and fully understand the test content, process and possible adverse reactions; 2. Male participants aged 18 years and older, male weight ≥50.0kg, body mass index (BMI) of 19 to 30kg/m2; 3. Patients with histopathologically diagnosed prostate cancer who were judged by investigators to be suitable for endocrine therapy, including 1 who had not received gonadotropin-releasing hormone analogues (GnRHa); 2 Patients receiving stable treatment with triprerelin acetate for injection; 3 Patients who have previously been treated with a gonadotropin-releasing hormone analogue (GnRHa) and who have been evaluated by the investigators as suitable for treatment with GNRHA; 4. ECOG score ≤2 points; 5. Expected survival ≥ 9 months; 6. Adequate hematopoietic function, liver and kidney function; 7. The subject is willing to have no family planning, sperm donation plan and voluntarily use one or more non-drug contraceptive methods (such as barrier contraception or abstinence) for 6 months from the signing of the information to the end of the drug administration.

-

Exclusion Criteria:

1. Patients who have previously undergone surgical castration; 2. Patients with known or suspected definite signs and symptoms of BMS or definite diagnosis of BMS; 3. Concurrent malignant tumors other than prostate cancer within 5 years, excluding basal cell carcinoma or squamous cell carcinoma of the skin that has been surgically removed; 4. Patients who have previously undergone adrenalectomy or pituitary resection or have pituitary disease; 5. Those who plan to undergo prostate surgery or other major surgical treatment during the study period (except urinary tract obstruction removal); 6. Patients with past or suspected spinal cord compression or urinary tract obstruction leading to kidney injury or patients at risk of developing such phenomena; 7. Patients with severe cardiovascular and cerebrovascular diseases, including but not limited to: patients with poorly controlled hypertension (systolic blood pressure \>160 mmHg and/or diastolic blood pressure \>100 mmHg under regular medication control); Patients with a history of hypertensive crisis or hypertensive encephalopathy; Severe cardiovascular and cerebrovascular disease, such as myocardial infarction, or heart failure classified by the New York Heart Association ≥II, within 6 months before the first administration of the investigational drug; Severe cardiac arrhythmia that cannot be controlled by medication (including QTc interval ≥470 ms), or congenital long QT syndrome; 8. Type I diabetes; Patients with type 2 diabetes with poor glycemic control (HbA1c\>8.0% at screening); 9. Hepatitis B Surface antigen (HBsAg) test positive with HBV-DNA greater than 104copies/mL(or 2000IU/mL), or hepatitis C antibody positive with HCV-RNA test positive, or HIV antibody positive, Or syphilis antibody positive and RPR or TRUST positive; 10. Previous history of severe asthma or severe anaphylaxis or severe urticaria and/or vasogenic edema; 11. Persons known to be allergic to any component of triprerelin acetate for injection or to GnRH analogues; 12. People who are currently abusing drugs, drugs or alcohol (drinking an average of more than 14 units of alcohol per week, 1 unit =360 mL of beer or 45 mL of 40% alcohol spirits or 150 mL of wine); 13. A drug known to prolong the QT interval or induce tip torsive ventricular tachycardia (e.g., Class IA (e.g., quinidine, propylamine) or Class III (amiodarone, sotalol, dofetilide, ibutilide) was taken for 4 weeks or 5 half-lives (whichever is longer) prior to administration (including induction and trial) Psychotics, methadone, moxifloxacin, antipsychotics, etc; 14. Those who participate in other clinical trials and receive clinical trial drugs or devices within 1 month before administration (including the introduction period and the trial period); 15. Those who received any vaccine within 4 weeks prior to administration (including the introduction and trial period); 16. People who ingested special diet (such as grapefruit, pomelo and its products) within 48 hours before administration (including the introduction period and the trial period), or other factors that may affect drug absorption, distribution, metabolism, excretion and so on; 17. Those who donated blood or lost a large amount of blood (≥200mL) within 1 month before administration (including the introduction period and the trial period), and received blood transfusion or platelet transfusion ≥2 therapeutic amounts (1 therapeutic amount =12U platelet); 18. Patients with difficulty in venous blood collection; 19. Other circumstances in which the investigator considers it inappropriate to participate in the clinical trial, or in which the participant's participation in the trial may affect the trial results or his or her own safety.

-

Primary outcomes:
measure: Peak Plasma Concentration (Cmax)
timeFrame: 672 hours
measure: Area under the plasma concentration versus time curve (AUC0-28d)
timeFrame: 28 days
measure: Area under the plasma concentration versus time curve (AUC7-28d)
timeFrame: 28 days
Secondary outcomes:
Other outcomes:
Locations:
city: Qingdao
country: China
facility: The Affiliated Hospital of Qingdao University
state: Shandong
Study officials:
References: